

Paradigm Shifts in Early Stage Breast Cancer

The Role of Neoadjuvant and Post-Neoadjuvant Therapies

CONFERENCE CHAIRS

Lajos Pusztai, MD, DPhil
Brian Czerniecki, MD

Eleftherios Mamounas, MD
Ruta Rao, MD

SATURDAY, August 24, 2019

7:50 AM – 3:30 PM

(Sign-in/Breakfast/Exhibits begin at 7:00 AM)

Rush University

1725 West Harrison Street
Searle Conference Center, Brainard Room, Suite 542
Chicago, IL

AGENDA and FACULTY

7:00 – 7:50 AM
7:50 – 8:00 AM

Sign-in/Exhibits/Breakfast
Welcome

Session I — The importance of pathologic complete response

8:00 – 8:20 AM	Brigid Killelea, MD (Yale University): The current landscape of neoadjuvant and adjuvant chemotherapy use in the USA
8:20 – 8:40 AM	Sunil Badve, MD (Indiana U): The prognostic importance of residual cancer burden after neoadjuvant chemotherapy
8:40 – 9:00 AM	Donald Berry, PhD (MDACC): Why survival improvement can be small despite substantial improvement in pathologic complete response rate
9:00 – 9:20 AM	Lajos Pusztai, MD, DPhil (Yale University): Neoadjuvant versus adjuvant chemotherapy
9:20 – 9:30 AM	Q & A
9:30 – 9:50 AM	Break/Exhibits

Session II — The role of neoadjuvant therapies in TNBC and HER2+ disease

9:50 – 10:20 AM	William J. Gradishar, MD (Northwestern U): Standard of care neoadjuvant/adjuvant therapies for TNBC, the current NCCN recommendations
10:20 – 10:40 AM	Charles Geyer, MD (VCU Massey): Neoadjuvant therapy of HER2 Positive breast cancer
10:40 – 11:00 AM	Rita Nanda, MD (U Chicago): Innovative combination therapies in the neoadjuvant setting to improve pCR rates: the I-SPY2 experience
11:00 – 11:20 AM	Hiroyuki Abe, MD, PhD (U Chicago): Imaging assessment of breast cancer before, during, and after neoadjuvant therapy
11:20 – 11:40 AM	Sunil Badve, MD (Indiana U): Tumor infiltrating lymphocytes and other predictors of response to neoadjuvant chemotherapy
11:40 – 11:50 AM	Q & A
11:50 AM – 12:50 PM	Lunch/Exhibits

Session III — The post-neoadjuvant therapies in TNBC and HER2+ breast cancer

12:50 – 1:00 PM	Lajos Pusztai, MD, DPhil (Yale University): Post neoadjuvant treatment options for HER2 positive breast cancer with residual disease
1:00 – 1:20 PM	Eleftherios Mamounas, MD (Orlando Health UF Health Cancer Center): Post neoadjuvant treatment options for HER2 positive breast cancer with residual disease
1:20 – 1:40 PM	Nadine Tung, MD (Beth Israel Deaconess Medical Center): Opportunities to de-escalate care after pathologic complete response in HER2 positive breast cancer
1:40 – 2:00 PM	Brian Czerniecki, MD (Moffitt): Emerging concepts in Immune therapies for patients with residual disease
2:00 – 2:10 PM	Q & A
2:10 – 2:30 PM	Break/Exhibits
2:30 – 2:50 PM	Steve Chmura, MD (U Chicago): What is oligometas and why is NCI doing a Phase 3 trial integrating SBRT into the early M1 disease?
2:50 – 3:10 PM	Henry Kuerer, MD (MDACC): De-Escalation of breast and axillary surgery after neoadjuvant systemic therapy
3:10 – 3:20 PM	Q&A
3:20 – 3:30 PM	Concluding Remarks

This activity will provide 6.0 CME/CE credit hours. Additional info can be found on website.

Register/Additional Information

www.plexuscomm.com/2019bc